PPT-TENOFOVIR ALAFENAMIDE PHARMACOKINETICS

WITH AND WITHOUT COBICISTAT IN PREGNANCY Jeremiah D Momper 1 Brookie Best 1 Jiajia Wang 2 Alice Stek 3 Tim R Cressey 4 Sandra Burchett 5 Regis Kreitchmann 6 David E Shapiro. An HIV pre-exposure prophylaxis trial in Thailand: . participant adherence and study results . National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Division of HIV/AIDS Prevention. A collaborative project involving: The Bangkok Metropolitan Administration, the. John J. . Faragon. , . PharmD. , BCPS, AAHIV-P. Albany Medical Center Hospital. NY/NJ AIDS Education and Training Center. When to Start. DHHS: Changing Criteria for Initiating ART. CD4+ Count, cells/mm. Program. Improving Health. . . Promoting Wellness. QUARTERLY . SUMMARY. 3rd Quarter. October-December 2017. 2017/2018 Ryan White Grant Year. COUNTY HEALTH DEPARTMENTS . BY PHARMACY CATEGORY. PUTNAM. MARION. Treatment-naïve Patients . Clinical Instructor, Harvard Medical School. Director of Research, CRI New England. Vice Chair, INSIGHT Scientific Steering Committee. Boston, USA . Calvin Cohen, MD, MSc. A.Dravid. 1. ,A.Sadre. 2. ,S.Dhande. 1. , A.Borkar. 1. ,M.Kulkarni. 1. ,M.Dravid. 3. 1. . Ruby hall clinic, Department of HIV Medicine, . Pune. , India. 2. Ruby hall clinic, Department of Nephrology, . of HIV. . Convenience, tolerability, simplicity. New & Investigational Agents. “Quad” Pill- . Stribild. Released by FDA 08-27-12. Tenofovir Emtricitabine Cobicistat Elvitegravir. “Booster”. Program. Improving Health. . . Promoting Wellness. QUARTERLY . SUMMARY. 2nd Quarter. July-September 2017. 2017/2018 Ryan White Grant Year. COUNTY HEALTH DEPARTMENTS . BY PHARMACY CATEGORY. PUTNAM. MARION. in a Single-Tablet Regimen . in Initial HIV-1 Therapy. Combined Primary Results of . Studies GS-US-292-0104 and GS-US-292-0111. David Wohl. 1. , Anton Pozniak. 2. , Melanie Thompson. 3. , Edwin DeJesus. TOTEM. Switching the NRTI Backbone to Tenofovir DF-Emtricitabine. TOTEM: Study Design. Source. : . Valantin. MA, et al. . J . Antimicrob. . Chemother. . 2010;65:556-61.. TDF-FTC + Continue . 3. rd. STEAL. Switch NRTIs to Tenofovir DF-Emtricitabine or Abacavir-Lamivudine. STEAL: Study Design. Source: . Martin A, et al. . Clin. Infect . Dis. 2009;49:1591. -1601. .. Study Design: STEAL. Background. ADONE Trial. Simplification to Efavirenz-Tenofovir DF-Emtricitabine . ADONE: Study Design. Source: . Airoldi. M, et al. Patient Prefer Adherence. 2010;4:115-25.. Study Design: ADONE Study . Background. Diese Präsentation dient ausschließlich der wissenschaftlichen Information gegenüber ärztlichen Fachkreisen. . Die Präsentation enthält keine werblichen Aussagen und dient nicht zu Werbezwecken. . FTC. Study 311-1089. Switching from TDF/FTC to TAF/. FTC. Study 311: Design. Source. : Gallant JE, et al. Lancet HIV. 2016;3:e158-65.. Switch to TAF/FTC*. . (n = 333). Continue TDF/FTC. (n = 330). *Patients on a pharmacokinetic booster (ritonavir) received tenofovir alafenamide-emtricitabine 10/200 mg. Tenofovir. . Disoproxil. . Fumarate. to . Tenofovir. . Alafenamide. Have Improved Renal and Bone Safety through 48 Weeks. Study GS-US-292-0112. Samir K. Gupta. 1. , Anton Pozniak. 2. , Jose Arribas.